Shanghai New World Past Earnings Performance
Past criteria checks 3/6
Shanghai New World's earnings have been declining at an average annual rate of -7.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 7.3% per year. Shanghai New World's return on equity is 1.1%, and it has net margins of 4%.
Key information
-7.7%
Earnings growth rate
-7.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -7.3% |
| Return on equity | 1.1% |
| Net Margin | 4.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Shanghai New World makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,134 | 45 | 333 | 0 |
| 30 Jun 24 | 1,142 | 40 | 335 | 0 |
| 31 Mar 24 | 1,145 | 34 | 339 | 0 |
| 31 Dec 23 | 1,134 | 32 | 329 | 0 |
| 30 Sep 23 | 1,075 | 32 | 337 | 0 |
| 30 Jun 23 | 1,049 | 18 | 323 | 0 |
| 31 Mar 23 | 905 | -39 | 306 | 0 |
| 31 Dec 22 | 850 | -52 | 294 | 0 |
| 30 Sep 22 | 903 | -44 | 276 | 0 |
| 30 Jun 22 | 938 | -24 | 290 | 0 |
| 31 Mar 22 | 1,106 | 56 | 308 | 0 |
| 31 Dec 21 | 1,166 | 69 | 325 | 0 |
| 30 Sep 21 | 1,171 | 133 | 207 | 0 |
| 30 Jun 21 | 1,168 | 132 | 252 | 0 |
| 31 Mar 21 | 1,114 | 108 | 260 | 0 |
| 31 Dec 20 | 1,046 | 71 | 311 | 0 |
| 30 Sep 20 | 1,129 | 4 | 489 | 0 |
| 30 Jun 20 | 1,100 | -37 | 483 | 0 |
| 31 Mar 20 | 1,133 | -58 | 498 | 0 |
| 31 Dec 19 | 1,653 | 37 | 492 | 0 |
| 30 Sep 19 | 2,043 | 82 | 496 | 0 |
| 30 Jun 19 | 2,431 | 151 | 508 | 0 |
| 31 Mar 19 | 2,773 | 227 | 505 | 0 |
| 31 Dec 18 | 2,776 | 273 | 507 | 0 |
| 30 Sep 18 | 2,841 | 270 | 555 | 0 |
| 30 Jun 18 | 2,948 | 282 | 551 | 0 |
| 31 Mar 18 | 2,988 | 305 | 563 | 0 |
| 31 Dec 17 | 3,022 | 448 | 558 | 0 |
| 30 Sep 17 | 3,002 | 632 | 507 | 0 |
| 30 Jun 17 | 2,968 | 582 | 519 | 0 |
| 31 Mar 17 | 2,971 | 509 | 502 | 0 |
| 31 Dec 16 | 3,018 | 253 | 504 | 0 |
| 30 Sep 16 | 3,034 | 57 | 419 | 0 |
| 30 Jun 16 | 3,060 | 49 | 413 | 0 |
| 31 Mar 16 | 3,090 | 24 | 418 | 0 |
| 31 Dec 15 | 3,114 | 52 | 426 | 0 |
| 30 Sep 15 | 3,203 | 114 | 400 | 0 |
| 30 Jun 15 | 3,213 | 142 | 403 | 0 |
| 31 Mar 15 | 3,250 | 232 | 411 | 0 |
| 31 Dec 14 | 3,333 | 240 | 407 | 0 |
| 30 Sep 14 | 3,422 | 243 | 404 | 0 |
| 30 Jun 14 | 3,432 | 239 | 410 | 0 |
| 31 Mar 14 | 3,470 | 245 | 409 | 0 |
| 31 Dec 13 | 3,450 | 243 | 406 | 0 |
Quality Earnings: 600628 has a large one-off loss of CN¥34.8M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 600628's current net profit margins (4%) are higher than last year (2.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600628's earnings have declined by 7.7% per year over the past 5 years.
Accelerating Growth: 600628's earnings growth over the past year (43.6%) exceeds its 5-year average (-7.7% per year).
Earnings vs Industry: 600628 earnings growth over the past year (43.6%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 600628's Return on Equity (1.1%) is considered low.